Cyclosporine-induced parkinsonism.
Marco A
MA
Lima
Simone
S
Maradei
Pericles
P
Maranhao Filho
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D002230:Carbidopa / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006408:Hematoma, Subdural / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000628:therapy; D007980:Levodopa / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D033581:Stem Cell Transplantation
D000978:Antiparkinson Agents; D007166:Immunosuppressive Agents; D007980:Levodopa; D016572:Cyclosporine; D002230:Carbidopa